An ascending multiple dose study of the safety, pharmacokinetics, and pharmacodynamics of SCA-136 [vabicaserin] administered orally to healthy Japanese and non-Japanese female subjects
Phase of Trial: Phase I
Latest Information Update: 11 Sep 2007
At a glance
- Drugs Vabicaserin (Primary)
- Indications Bipolar disorders
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors Wyeth
- 11 Sep 2007 Status change from recruiting to completed.
- 17 Apr 2007 New trial record.